Do analysts rate MOLN or AVTE?

Molecular Partners currently has a consensus price target of $8.38, indicating a potential upside of 103.28%. Given Molecular Partners' stronger consensus rating and higher possible upside, equities research analysts plainly believe Molecular Partners is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MOLN or AVTE more profitable?

Molecular Partners' return on equity of -66.62% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media refer more to MOLN or MDXG?

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.75 beat MiMedx Group's score of 0.46 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MOLN or ALT?

In the previous week, Altimmune had 4 more articles in the media than Molecular Partners. MarketBeat recorded 5 mentions for Altimmune and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Altimmune's score of 0.15 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MOLN or CTMX?

In the previous week, CytomX Therapeutics had 7 more articles in the media than Molecular Partners. MarketBeat recorded 8 mentions for CytomX Therapeutics and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat CytomX Therapeutics' score of -0.67 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Negative

Is NGNE or MOLN more profitable?

Neurogene's return on equity of -37.88% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Molecular Partners N/A -66.62% -54.85%

Does the media prefer NGNE or MOLN?

In the previous week, Neurogene had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Neurogene's score of 0.34 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Molecular Partners (MOLN) Competitors

$4.12 +0.07 (+1.73%)

As of 02:37 PM Eastern

Compare

MOLN vs. AVTE, MDXG, ALT, CTMX, and NGNE

Should you buy Molecular Partners stock or one of its competitors? Molecular Partners's main competitors and comparable companies include Aerovate Therapeutics (AVTE), MiMedx Group (MDXG), Altimmune (ALT), CytomX Therapeutics (CTMX), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Molecular Partners compare to Aerovate Therapeutics?

Molecular Partners (NASDAQ:MOLN) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

26.6% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Molecular Partners has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Molecular Partners had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Molecular Partners and 0 mentions for Aerovate Therapeutics. Molecular Partners' average media sentiment score of 0.75 beat Aerovate Therapeutics' score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Positive
Aerovate Therapeutics	Neutral

Molecular Partners currently has a consensus price target of $8.38, indicating a potential upside of 103.28%. Given Molecular Partners' stronger consensus rating and higher possible upside, equities research analysts plainly believe Molecular Partners is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Molecular Partners' return on equity of -66.62% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Molecular Partners beats Aerovate Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Molecular Partners compare to MiMedx Group?

Molecular Partners (NASDAQ:MOLN) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 103.28%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 99.06%. Given Molecular Partners' higher probable upside, equities research analysts clearly believe Molecular Partners is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A
MiMedx Group	$418.63M	1.49	$48.58M	$0.04	106.75

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.75 beat MiMedx Group's score of 0.46 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Molecular Partners' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
MiMedx Group	1.76%	12.09%	9.22%

Molecular Partners has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

MiMedx Group beats Molecular Partners on 11 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Altimmune?

Molecular Partners (NASDAQ:MOLN) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 103.28%. Altimmune has a consensus price target of $15.71, indicating a potential upside of 415.22%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Altimmune had 4 more articles in the media than Molecular Partners. MarketBeat recorded 5 mentions for Altimmune and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Altimmune's score of 0.15 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A

Molecular Partners has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Altimmune	-214,860.98%	-42.57%	-35.57%

Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Altimmune beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to CytomX Therapeutics?

Molecular Partners (NASDAQ:MOLN) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 103.28%. CytomX Therapeutics has a consensus target price of $12.00, indicating a potential upside of 248.84%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, CytomX Therapeutics had 7 more articles in the media than Molecular Partners. MarketBeat recorded 8 mentions for CytomX Therapeutics and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat CytomX Therapeutics' score of -0.67 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Negative

CytomX Therapeutics has higher revenue and earnings than Molecular Partners. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A
CytomX Therapeutics	$76.20M	7.68	-$17.37M	-$0.50	N/A

Molecular Partners has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Molecular Partners has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Summary

CytomX Therapeutics beats Molecular Partners on 12 of the 17 factors compared between the two stocks.

How does Molecular Partners compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Neurogene had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.75 beat Neurogene's score of 0.34 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene currently has a consensus target price of $84.83, indicating a potential upside of 132.10%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 103.28%. Given Neurogene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurogene is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Molecular Partners has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	620.96	-$90.35M	-$4.55	N/A
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neurogene's return on equity of -37.88% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Molecular Partners	N/A	-66.62%	-54.85%

Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Neurogene beats Molecular Partners on 11 of the 16 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163.52M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.12	5.30	210.34	20.96
Price / Sales	29.45	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	1.72	17.66	11.27	6.42
Net Income	-$74.41M	-$13.25M	$3.45B	$347.03M
7 Day Performance	-1.44%	5.36%	3.56%	2.48%
1 Month Performance	1.70%	-1.74%	-0.58%	-1.04%
1 Year Performance	15.70%	61.36%	77.52%	23.22%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	2.4918 of 5 stars	$4.12 +1.7%	$8.38 +103.3%	+15.4%	$163.52M	$5.65M	N/A	180
AVTE Aerovate Therapeutics	N/A	$21.35 +11.5%	N/A	+193.2%	$618.83M	N/A	N/A	20	Gap Up High Trading Volume
MDXG MiMedx Group	2.8 of 5 stars	$4.16 -2.6%	$8.50 +104.3%	-38.2%	$606.36M	$418.63M	104.03	870
ALT Altimmune	2.0975 of 5 stars	$3.03 -1.3%	$15.71 +418.6%	-10.7%	$589.24M	$40K	N/A	50	Upcoming Earnings
CTMX CytomX Therapeutics	1.9726 of 5 stars	$3.35 +0.9%	$12.10 +261.2%	+47.2%	$570.13M	$35.54M	N/A	170	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. AVTE, MDXG, ALT, CTMX, and NGNE

How does Molecular Partners compare to Aerovate Therapeutics?

Summary

How does Molecular Partners compare to MiMedx Group?

Summary

How does Molecular Partners compare to Altimmune?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Summary

How does Molecular Partners compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. AVTE, MDXG, ALT, CTMX, and NGNE

How does Molecular Partners compare to Aerovate Therapeutics?

Which has more volatility and risk, MOLN or AVTE?

Do institutionals & insiders believe in MOLN or AVTE?

Which has preferable earnings and valuation, MOLN or AVTE?

Does the media prefer MOLN or AVTE?

Do analysts rate MOLN or AVTE?

Is MOLN or AVTE more profitable?

Summary

How does Molecular Partners compare to MiMedx Group?

Do insiders and institutionals believe in MOLN or MDXG?

Do analysts rate MOLN or MDXG?

Which has stronger valuation and earnings, MOLN or MDXG?

Does the media refer more to MOLN or MDXG?

Is MOLN or MDXG more profitable?

Which has more risk and volatility, MOLN or MDXG?

Summary

How does Molecular Partners compare to Altimmune?

Do analysts prefer MOLN or ALT?

Does the media prefer MOLN or ALT?

Which has higher valuation and earnings, MOLN or ALT?

Is MOLN or ALT more profitable?

Which has more volatility & risk, MOLN or ALT?

Do insiders & institutionals believe in MOLN or ALT?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Do analysts rate MOLN or CTMX?

Does the media refer more to MOLN or CTMX?

Which has higher valuation & earnings, MOLN or CTMX?

Is MOLN or CTMX more profitable?

Do insiders and institutionals believe in MOLN or CTMX?

Which has more risk & volatility, MOLN or CTMX?

Summary

How does Molecular Partners compare to Neurogene?

Does the media prefer NGNE or MOLN?

Do analysts prefer NGNE or MOLN?

Which has better earnings and valuation, NGNE or MOLN?

Do insiders & institutionals believe in NGNE or MOLN?

Is NGNE or MOLN more profitable?

Which has more volatility & risk, NGNE or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools